Core Insights - BridgeBio Oncology Therapeutics, Inc. (BBOT) is a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies and has announced poster presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics [1][2] Company Overview - BBOT is advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies, aiming to improve outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors [3] Conference Presentations - The company will present BBO-11818, an orally bioavailable, highly potent and selective non-covalent pan-KRAS inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models during a poster session on October 23 [4] - Another presentation will feature BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction, which inhibits tumor growth alone and in combination with KRAS inhibitors in KRAS mutant models without inducing hyperglycemia, scheduled for October 25 [4]